Title:
ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
Document Type and Number:
Japanese Patent JP7488854
Kind Code:
B2
Abstract:
The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that thehalf-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereofcan be long-lasting.
More Like This:
Inventors:
Kim Yong Sung
Jeong Kung Ok
Hachihi
Kim Ye Chin
Choi Dong Ki
Chehechi
Jeong Kung Ok
Hachihi
Kim Ye Chin
Choi Dong Ki
Chehechi
Application Number:
JP2022116329A
Publication Date:
May 22, 2024
Filing Date:
July 21, 2022
Export Citation:
Assignee:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
International Classes:
C07K19/00; A61K38/20; A61K39/395; A61K47/68; A61P35/00; C12N15/62
Domestic Patent References:
| JP2001525423A | ||||
| JP2016506377A |
Other References:
GILLIES, SD et al.,Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases,The Journal of Immunology,1998年,Vol. 160,pp. 6195-6203
GUNASEKARAN, K et al.,Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects,Journal of Biological Chemistry,2010年,Vol. 285, No. 25,pp. 19637-19646
GUNASEKARAN, K et al.,Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects,Journal of Biological Chemistry,2010年,Vol. 285, No. 25,pp. 19637-19646
Attorney, Agent or Firm:
Shusaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto